Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.66 and traded as high as $3.28. Ironwood Pharmaceuticals shares last traded at $3.2460, with a volume of 583,965 shares.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on IRWD shares. Wells Fargo & Company boosted their price objective on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.34.

Ironwood Pharmaceuticals Stock Performance

The firm has a market capitalization of $528.06 million, a P/E ratio of 20.29 and a beta of 0.18. The firm has a 50 day moving average price of $2.83 and a two-hundred day moving average price of $1.66.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%.The business had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IRWD. Integrated Wealth Concepts LLC raised its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares during the period. McAdam LLC purchased a new position in Ironwood Pharmaceuticals during the 1st quarter worth approximately $40,000. Vise Technologies Inc. acquired a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at $39,000. BNP Paribas Financial Markets raised its stake in Ironwood Pharmaceuticals by 83.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 15,594 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in shares of Ironwood Pharmaceuticals in the second quarter valued at $25,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.